The relationship between mutant p53 gene, DNA contents and conventional clinicopathological prognostic variables in cases with endometrial carcinoma

Purpose of investigation: To determine whether p53 expression and DNA ploidy are related to traditional prognostic indicators in patients with endometrial cancer.

Methods: Tumor material (n=136) was analyzed regarding flow cytometric DNA ploidy and immunohistochemical p53 expression. Pearson's correlation, Fisher's exact test, Cox's regression analysis and the Kaplan-Meier survival test were used, as appropriate.

Results: P53 overexpression and DNA ploidy were higher in patients with nonendometrioid histology, FIGO advanced stage, poor grade, positive peritoneal cytology, lymphovascular space invasion (LVSI) and lymph node involvement (LNI). Histologic subtype, stage, grade, LVSI, LNI, tumor recurrence and overall survival rate correlated with p53 and DNA ploidy. No association of depth of myometrial invasion and age with p53 and DNA ploidy was observed. P53 was related to DNA ploidy. Of the factors analyzed, histologic subtype and myometrial invasion were found to be most important independent determinants of recurrence. Utilizing survival as the endpoint for multivariate analysis, when considering p53 and DNA ploidy together, histologic subtype, stage, peritoneal cytology, LNI and DNA ploidy were independent prognostic indicators.

Conclusion: p53 expression and DNA ploidy were related to histologic subtype, FIGO stage, grade, LVSI, LNI, peritoneal cytology, tumor recurrence and overall 5-year survival. As compared to p53, DNA ploidy was the stronger independent predictor factor for survival. Neither p53 nor DNA ploidy were significant independent factors for tumor recurrence when submitted to multivariate analysis in this study. However, since p53 or DNA ploidy were found to be significant factors in univariate analysis and were correlated with tumor recurrence, they could be useful factors in making prognoses.

Endometrial cancer; p53; DNA ploidy; Prognostic factors

[1] Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., Thun M.J.: "Cancer statistics". Cancer J. Clin., 2003, 53, 5.

[2] Lanciano R.M., Com B.W., Schultz DJ., Kramer C.A., Rosenblum N., Hogan W.M.: "The justification for a surgical staging system in endometrial carcinoma". Radiother. Oncol., 1993, 28, 189.

[3] Mayr N.A., Wen B.C., Benda J.A., Sorosky J.I., Davis C.S., Fuller R.W. et al.: "Postoperative radiation therapy in clinical stage I endometrial cancer: corpus, cervical, and lower uterine segment involvement-patterns of failure". Radiology, 1995, 196, 323.

[4] el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M. et al.: "WAFI, a potential mediator of p53 tumor suppression". Cell., 1993, 75, 817.

[5] Harris C.C.: "Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies". J. Natl. Cancer Inst., 1996, 88, 1442.

[6] Ito K., Watanabe K., Nasim S., Sasano H., Sato S., Yajima A. et al.: "Prognostic significance of p53 overexpression in endometrial cancer". Cancer Res., 1994, 54, 4667.

[7] Kohlberger P., Gitsch G., Loesch A., Tempfer C., Kaider A., Reinthaller A. et al.: "p53 protein overexpression in early stage endometrial cancer". Gynecol. Oncol., 1996, 62, 213.

[8] Geisler J.P., Wiemann M.C., Zhou Z., Miller G.A., Geisler H.E.: "p53 as a prognostic indicator in endometrial cancer". Gynecol. Oncol., 1996, 61, 245.

[9] Lukes A.S., Kohler M.F., Pieper C.F., Kerns B.J., Bentley R., Rodriguez G.C. et al.: "Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer". Cancer, 1994, 73, 2380.

[10] Ambros R.A., Sheehan C.E., Kallakury B.V., Ross J.S., Malfetano J., Paunovich E. et al.: "MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma". Mod. Pathol., 1996, 9, 1165.

[11] Kohler M.F., Berchuck A., Davidoff A.M., Humphrey P.A., Dodge R.K., Iglehart J.D. et al.: "Overexpression and mutation of p53 in endometrial carcinoma". Cancer Res., 1992, 52, 1622.

[12] Hamel N.W., Sebo T.J., Wilson T.0., Keeney G.L., Roche P.C., Suman VJ. et al.: "Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma". Gynecol. Oncol., 1996, 62, 192.

[13] Reinartz J.J., George E., Lindgren B.R., Niehans G.A.: "Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival". Hum. Pathol., 1994, 25, 1075.

[14] Erdem O., Erdem M., Dursun A., Akyol G., Erdem A.:''Angiogenesis, p53, and bcl-2 expression as prognostic indicators in endometrial cancer: comparison with traditional clinicopathologic variables". Int. J. Gynecol. Pathol., 2003, 22, 254.

[15] Nielsen A.L., Nyholm H.C.: "p53 protein and c-erbB-2 protein (pl 85) exp ression in endometrial adenocarcinoma of endometrioid type. An immunohistochemical examination on paraffin sections". Am. J. Clin. Pathol., 1994, 102, 76.

[16] Lundgren C., Auer G., Frankendal B., Moberger B., Nilsson B., Nordstrom B.: "Nuclear DNA content, proliferative activity, and p53 expression related to clinical and histopathologic features in endometrial carcinoma". Int. J. Gynecol. Cancer, 2002, 12, 110.

[17] Nordstrom B., Strang P., Lindgren A., Bergstrom R., Tribukait B.: "Endometrial carcinoma: the prognostic impact of papillary serous carcinoma (UPSC) in relation to nuclear grade, DNA ploidy and p53 expression". Anticancer Res., 1996, 16, 899.

[18] Britton L.C., Wilson T.O., Gaffey T.A., Cha S.S., Wieand H.S., Podratz K.C.: "DNA ploidy in endometrial carcinoma: major objective prognostic factor". Mayo Clin. Proc., 1990, 65, 643.

[19] Hedley D.W., Friedlander M.L., Taylor I.W., Rugg C.A., Musgrove E.A.: "Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry". J. Histochem. Cytochem., 1983, 31, 1333.

[20] Strang P., Nordstom B., Nilsson S., Bergstrom R., Tribukait B.: "Mutant p53 protein as a predictor of survival in endometrial carcinoma". Eur. J. Cancer, 1996, 32, 598.

[21] Nielsen A.L., Nyholm H.C.: "The combination of p53 and age predict cancer specific death in advanced stage (FIGO le-IV) of endometrial carcinoma of endometrioid type. An immunohistochemical examination of growth fraction: Ki-67, MIB- 1 and PC lO; suppressor oncogene protein: p53; oncogene protein: p185 and age, hormone treatment, stage, and histologic grade". Eur. J. Obstet. Gynecol. Reprod. Biol., 1996, 70, 79.

[22] Pfisterer J., Kommoss F., Sauerbrei W., Renz H., du Bois A., Kiechle-Schwarz M. et al.: "Prognostic value of DNA ploidy and S-phase fraction in Stage I endometrial carcinoma". Gynecol Oncol., 1995, 58, 149.

[23] Lindahl B., Alm P., Ferno M., Killander D., Langstrom E., Norgren A. et al.: "Prognostic value of steroid receptor concentration and flow cytometrical DNA measurements in Stage I-II endometrial carcinoma". Acta Oncol., 1989, 28, 595.

[24] Rosenberg P., Wingren S., Simonsen E., Stal 0., Risberg B., Nordenskjold B.: "Flow cytometric measurements of DNA index and S-phase on paraffin-embedded early stage endometrial cancer: an important prognostic indicator". Gynecol. Oncol., 1989, 35, 50.

[25] Newbury R., Schuerch C., Goodspeed N., Fanning J., Glidewell o., Evans M.: "DNA content as a prognostic factor in endometrial carcinoma". Obstet. Gynecol., 1990, 76, 251

[26] Riethdorf L., Begemann C., Riethdorf S., Milde-Langosch K., Loning T.: "Comparison of benign and malignant endometrial lesions for their p53 state, using immunohistochemistry and temperature- gradient gel electrophoresis". ½rchows Arch., 1996, 428, 47.

[27] Iversen O.E.: "Flow cytometric deoxyribonucleic acid index: a prognostic factor in endometrial carcinoma". Arn. J. Obstet Gynecol., 1986, 155, 770.

[28] Larson D.M., Berg R., Shaw G., Krawisz B.R.: "Prognostic significance of DNA ploidy in endometrial cancer". Gynecol. Oneal., 1999, 74, 356.

[29] Susini T., Rapi S., Massi D., Savino L., Amunni G., Taddei G.L et al.: "Pr_eoperative eval􀃐atio􀃑 of t􀃒mor ploidy in_e􀃓d?metrial carcinoma: An accurate tool to identify patients at risk for extrauterine disease and recurrence". Cancer, 1999, 86, 1005.